Literature DB >> 7515446

Genetic susceptibility of benign prostatic hyperplasia.

M G Sanda1, T H Beaty, R E Stutzman, B Childs, P C Walsh.   

Abstract

In an effort to provide new insight into the etiology of benign prostatic hyperplasia (BPH), an evaluation of genetic factors was performed. Recognizing that early age of onset is a marker for hereditary disease, we performed a case-control study of men with early onset of significant BPH. Men in the youngest quartile (less than 64 years old) with a large prostate (greater than 37 gm. resected tissue) who underwent surgery for BPH were identified as case probands from 909 consecutive prostatectomies for BPH. Control probands, selected because of the ability to distinguish treatment for benign prostate disease from treatment for malignant prostate disease, were women whose spouses underwent radical prostatectomy during the same interval. Male relatives of men with early onset of BPH had a 66% cumulative lifetime risk of prostatectomy for BPH, compared to a 17% cumulative risk among control relatives (p = 0.001). A 4-fold increase in age-specific risk of prostatectomy for BPH was present among relatives of men who had undergone prostatectomy for BPH (p = 0.0003), while brothers of these affected cases had a 6-fold increase in risk (p = 0.0089) compared to controls. To determine the likelihood that genetic factors account for this familial aggregation of BPH, segregation analysis was done. Although the small sample size prevented rigorous exclusion of nongenetic models, direct comparison of mendelian and nongenetic models showed that mendelian transmission provided the best overall explanation of the observed familial aggregation. The optimal model suggested mendelian dominant inheritance of a gene associated with early age at onset of BPH. These findings identify family history of BPH as a risk factor for clinical BPH and suggest the presence of a predisposing gene in patients with early onset BPH. Evidence of dominant mendelian transmission of this allele provides a framework for genetic studies to characterize this gene and elucidate the development of BPH in general.

Entities:  

Mesh:

Year:  1994        PMID: 7515446     DOI: 10.1016/s0022-5347(17)32831-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

Review 1.  The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.

Authors:  Edward D Kim
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

Review 2.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

Review 3.  Benign prostatic hyperplasia.

Authors:  R J Simpson
Journal:  Br J Gen Pract       Date:  1997-04       Impact factor: 5.386

4.  SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.

Authors:  Danyelle Winchester; Luisel Ricks-Santi; Tshela Mason; Muneer Abbas; Robert L Copeland; Desta Beyene; Emmanuel Y Jingwi; Georgia M Dunston; Yasmine M Kanaan
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

Review 5.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

6.  Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk.

Authors:  Xian-Tao Zeng; Qi-Sheng Yao; Hong Weng; Sheng Li; Jing-Yu Huang; Xing-Huan Wang
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

Review 7.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 8.  Biomarkers for benign prostatic hyperplasia progression.

Authors:  Grant W Cannon; Robert H Getzenberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

9.  Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy.

Authors:  K Shibata; A Hirasawa; N Moriyama; K Kawabe; S Ogawa; G Tsujimoto
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.

Authors:  Anne K Mongiu; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.